{"name":"ADMA Biologics, Inc.","slug":"adma-biologics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":42219783,"revenueGrowth":43.9,"grossMargin":693.4,"rdSpend":4762000,"netIncome":146930000,"cash":87630000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2020"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"RI-002","genericName":"RI-002","slug":"ri-002","indication":"Primary immunodeficiency disorders","status":"phase_3"},{"name":"Asceniv™","genericName":"Asceniv™","slug":"asceniv","indication":"Primary immunodeficiency (PI) disorders","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Bivigam","genericName":"Bivigam","slug":"bivigam","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"RI-002","genericName":"RI-002","slug":"ri-002","phase":"phase_3","mechanism":"RI-002 is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering polyclonal human antibodies to boost immune function.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency in hematologic malignancies"],"catalyst":""},{"name":"Asceniv™","genericName":"Asceniv™","slug":"asceniv","phase":"marketed","mechanism":"Asceniv is an intravenous immunoglobulin (IVIG) replacement therapy that provides polyclonal antibodies to boost immune function in patients with primary immunodeficiency.","indications":["Primary immunodeficiency (PI) disorders"],"catalyst":""},{"name":"Bivigam","genericName":"Bivigam","slug":"bivigam","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNcGt2Tkw1V1dBdWE0Z3paT29RaGlfUWhYT0tqVmtETDdXdG5LNGxxckxvSHMwazNrMmRHeUlETmlPVzBaVTNJekxUUzhSM2E1b0JVR3FGOGptcmxrSnFzX2E3VHJLbXJTT1JjU3k4dnZQdG1EbWlwaTd2MVJQNHBOcGVfTGxNQkVjbWlUSGQwbmE0T25jV1ZTWmFDMzFaa0pZQ0ZSNA?oc=5","date":"2026-04-07","type":"pipeline","source":"National Today","summary":"Aberdeen Group Reduces ADMA Biologics Stake - National Today","headline":"Aberdeen Group Reduces ADMA Biologics Stake","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOYlJNNjJMdkdsekpoS3h2TDFIWWZZRGtZdnRGcXQ1V2ZjbjFOMERqWG1peTRWcUd0WGtILTBGWHpOWGhFLU0wejJDRlVVLVhBcTZxT1VSS0hOSW9JcVp2REJISld1YTktaHBZcmp0dHZ2ZXpPSkpqaV9mQWhIZkZ4NEVGYmZyY2FOZmlsbUdhZ2pjY0hNRGJyVTR5YmFET0o0NjFCWlpKTXZhcjIyWTltMVk1T01HdmJQYlE?oc=5","date":"2026-04-02","type":"deal","source":"TradingView","summary":"Janux Therapeutics Secures $35M Milestone Payment From BMY Deal - TradingView","headline":"Janux Therapeutics Secures $35M Milestone Payment From BMY Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNN2JuVXJyZFItOWxCMjBsaGgtYk0zRFE0OERBUmp5dHIwaVJlY0Q0TkJvb2lqazJVbzVNTGJMY2swZDdjeUZQR3lvS2lRc2Z2aEFVTk5uY21GSjh1ajBKX0l4d0ZhNnJCSkUwZS1HSWRaVGhMdmxha3htWWp2eDRIdk1URlByZVdLQW9rNmlxMTZzQVRzTEZGc3Fwa2ZwN2hqaXBobFVUTXdKSlh6VEhuUERBODA1SC1jYzdEdC04V2plMVk?oc=5","date":"2026-04-01","type":"deal","source":"TradingView","summary":"Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio - TradingView","headline":"Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQenh6RGtIeXZINXo2alNsUVN0RjVxMEhwcjlCRzJ3SHQ1dnE3RVVMUlZLLUg2V3N3TC1Zd1pjNGpHRDc1Q01yVlNMallRRkdPSFBlQlFNQ0Z5MFpGUzdobG1WVDJ5dmRTS2k0bVowal9nTmpJZ3VUUHh5U3NkT2tma25GWGhiZWN2U2RxNHYxR0RlTzlSeFE3V1FoTXVvWUtXREVGUHo4RGh4UkpzanVGTHBR?oc=5","date":"2026-03-27","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga","headline":"12 Health Care Stocks Moving In Friday's Intraday Session","sentiment":"neutral"},{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNelBRSkJqUkVsZDdsTkVCWGxzVGRDQkY3TGtDTlNpai15X1p3RC1BY3NUVjhQMWJsTnNZR2FOQjdKN3FHYmFSLVN0Z2pNQ3RWNVhCT05HZW1ZX1FHMFdnX3M4QWlUbV9iejI0S2JYeVg1T0tYX045SlFmcDJGVUpyVHpReVBNeENrMk5hemwyXzQ0M2RYeU5FVmFRUF9nZnNqd1hTeVo2eFhEU0x0ZmhCc0ZHWXByZVhJWDgwYWNKNjhiUGVFaXh2TGt5aXRIVXd6d0NvVjhqNmxiMjZITkpDakIwZU92X0hNVEE?oc=5","date":"2026-03-26","type":"pipeline","source":"Benzinga","summary":"This Qualcomm Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga","headline":"This Qualcomm Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOVzlhbVhBWllZUzNjUlB1WmxaYUNpSWRHQ21HZk9XR3lOTktkcHJNM3BpcU1Ic3J0b2M2MXM0aG53SW05NkNibTFFV2xqOE1YNlFfUFMxTGxJaWplMmtRRTRsay1zYWh4MEFtWWVUaWdnSHcwQmdiQkZkeUMzem9ibXBYaHZUaUp4TG9HdDRseEhWMnZpLWRhTmR2eUl2MTJjT3VPbzA1aU9uT3kzNlpqR3hOS3JyWkpqZS1DYlZSLWNFWjA?oc=5","date":"2026-03-25","type":"trial","source":"TradingView","summary":"NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data - TradingView","headline":"NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOMXdqVGlEelNuQ1dLZHdhOW1WM0hUZGk5REVHU19yNkM4djVVY29ZQUJZSDJrZXpIbU9OeVY5NFJ3cm1Mc19LOWx6a1dVT0ZLdUs1Ql9nS3RDNWZwMk9TQ19qVXRNOHhVZ1RBVlluQ3lRMWFndzMwTFd3RUJsZlUwNU1PTDZDb1B5RE13WkhR?oc=5","date":"2026-03-16","type":"pipeline","source":"Yahoo Finance","summary":"Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia - Yahoo Finance","headline":"Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-02","type":"pipeline","source":"simplywall.st","summary":"ADMA Biologics, Inc. (NASDAQ:ADMA) Looks Just Right With A 25% Price Jump - simplywall.st","headline":"ADMA Biologics, Inc. (NASDAQ:ADMA) Looks Just Right With A 25% Price Jump","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNaEZpMENGbmtDS3FSYnZCTWMwc0tvdU1STmNGdDZDa0djWTBoSHg0ZXFLbnhYTGN4SEp3UTBnOEx0U1NIaG96d2ZRSC1lX21SYU5uMmtDa09VUVZsUjZmTUlSc1diNVktWkRacm1pMlhkMThXa0tWT1BXZ2gxRHNyaWtDbzBTb1pPcXFqWVFn?oc=5","date":"2025-11-20","type":"deal","source":"Seeking Alpha","summary":"ADMA Biologics: Why The Dip To $16 Resets The Buy Case (NASDAQ:ADMA) - Seeking Alpha","headline":"ADMA Biologics: Why The Dip To $16 Resets The Buy Case (NASDAQ:ADMA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNVy1GOGFvVUwzQk9kWFdRS2xaMkpTQTk2Q0ZaUlpKdUFZbjZ5QWdQcUJWbGduRzZfZ0kwVG5KLTJfVkRUMzFRWkVRUFBYWmVjRU5GUlpCYzB4bGpKbjFvdEdOaklXc2FwT29NdzJnQjk5eVI4YlFMbEI5bnRzNE9XSExQYTdkRDY3VWZLTERR?oc=5","date":"2025-10-30","type":"pipeline","source":"Site Selection Magazine","summary":"Why a Key U.S. Drug Supplier is Doubling Down on Boca Raton - Site Selection Magazine","headline":"Why a Key U.S. Drug Supplier is Doubling Down on Boca Raton","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQREtwaWJwSFVBSzROTXlJQzktNHBlclFIX3RkUDFkdjZXQlNkRk12b1JKcUYzRGU0cmUteWc2ZGlFUDk4VUQxMVlpQjl3b3hqOENRUVNHRm1BbVlkQ283cVo5clc1MWJlbThienRsbjluaVZPYTlFRGNJenFndldIMDlvWl9rSnJrTkdVYk9fMjE3UzJaekFlQVBBVWtTNVhRT1VFdExubw?oc=5","date":"2025-02-12","type":"pipeline","source":"Schaeffer's Investment Research","summary":"Pharma Stock Poised to Bounce Off Support - Schaeffer's Investment Research","headline":"Pharma Stock Poised to Bounce Off Support - Schaeffer's Investment Research","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":1,"marketed":2},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":42219783,"revenuePeriod":"2020-12-31","revenueHistory":[{"value":42219783,"period":"2020-12-31"},{"value":29349083,"period":"2019-12-31"},{"value":16985290,"period":"2018-12-31"},{"value":4230310,"period":"2018-09-30"},{"value":4656550,"period":"2018-06-30"},{"value":4042006,"period":"2018-03-31"}],"grossProfit":292765000,"grossProfitHistory":[],"rdSpend":4762000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":146930000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":87630000,"cashHistory":[],"totalAssets":624242000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}